Determining the Degree of Dopaminergic Denervation Based on the Loss of Nigral Hyperintensity on SMWI in Parkinsonism

References

1. 1.↵
   1. Davie CA

   . A review of Parkinson’s disease. Br Med Bull 2008;86:109–27 doi:10.1093/bmb/ldn013 pmid:18398010

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Poewe W,
   2. Seppi K,
   3. Tanner CM, et al

   . Parkinson disease. Nat Rev Dis Primers 2017;3:17013 doi:10.1038/nrdp.2017.13 pmid:28332488

   CrossRefPubMed
3. 3.↵
   1. Damier P,
   2. Hirsch EC,
   3. Agid Y, et al

   . The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 1999;122:(Pt)1437–48 doi:10.1093/brain/122.8.1437 pmid:10430830

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Damier P,
   2. Hirsch EC,
   3. Agid Y, et al

   . The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999;122:1421–36 doi:10.1093/brain/122.8.1421 pmid:10430829

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Bae YJ,
   2. Kim JM,
   3. Kim E, et al

   . Loss of nigral hyperintensity on 3 Tesla MRI of Parkinsonism: comparison with (123) I-FP-CIT SPECT. Mov Disord 2016;31:684–92 doi:10.1002/mds.26584 pmid:26990970

   CrossRefPubMed
6. 6.↵
   1. Cosottini M,
   2. Frosini D,
   3. Pesaresi I, et al

   . Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease. AJNR Am J Neuroradiol 2015;36:461–66 doi:10.3174/ajnr.A4158 pmid:25376811

   Abstract/FREE Full Text
7. 7.↵
   1. Kim JM,
   2. Jeong HJ,
   3. Bae YJ, et al

   . Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Parkinsonism Relat Disord 2016;26:47–54 doi:10.1016/j.parkreldis.2016.01.023 pmid:26951846

   CrossRefPubMed
8. 8.↵
   1. Kwon DH,
   2. Kim JM,
   3. Oh SH, et al

   . Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71:267–77 doi:10.1002/ana.22592 pmid:22367998

   CrossRefPubMed
9. 9.↵
   1. Lehericy S,
   2. Bardinet E,
   3. Poupon C, et al

   . 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson’s disease. Mov Disord 2014;29:1574–81 doi:10.1002/mds.26043 pmid:25308960

   CrossRefPubMed
10. 10.↵
    1. Noh Y,
    2. Sung YH,
    3. Lee J, et al

    . Nigrosome 1 detection at 3T MRI for the diagnosis of early-stage idiopathic Parkinson disease: assessment of diagnostic accuracy and agreement on imaging asymmetry and clinical laterality. AJNR Am J Neuroradiol 2015;36:2010–16 doi:10.3174/ajnr.A4412 pmid:26294646

    Abstract/FREE Full Text
11. 11.↵
    1. Reiter E,
    2. Mueller C,
    3. Pinter B, et al

    . Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Mov Disord 2015;30:1068–76 doi:10.1002/mds.26171 pmid:25773707

    CrossRefPubMed
12. 12.↵
    1. Schwarz ST,
    2. Afzal M,
    3. Morgan PS, et al

    . The “swallow tail” appearance of the healthy nigrosome—a new accurate test of Parkinson’s disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One 2014;9:e93814 doi:10.1371/journal.pone.0093814 pmid:24710392

    CrossRefPubMed
13. 13.↵
    1. Mahlknecht P,
    2. Krismer F,
    3. Poewe W, et al

    . Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson’s disease. Mov Disord 2017;32:619–23 doi:10.1002/mds.26932 pmid:28151553

    CrossRefPubMed
14. 14.↵
    1. Seibyl JP,
    2. Kupsch A,
    3. Booij J, et al

    . Individual-reader diagnostic performance and between-reader agreement in assessment of subjects with Parkinsonian syndrome or dementia using 123I-ioflupane injection (DaTscan) imaging. J Nucl Med 2014;55:1288–96 doi:10.2967/jnumed.114.140228 pmid:24925885

    Abstract/FREE Full Text
15. 15.↵
    1. Suwijn SR,
    2. van Boheemen CJ,
    3. de Haan RJ, et al

    . The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Res 2015;5:12 doi:10.1186/s13550-015-0087-1 pmid:25853018

    CrossRefPubMed
16. 16.↵
    1. Tatsch K,
    2. Poepperl G

    . Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: an update. J Nucl Med 2013;54:1331–8 doi:10.2967/jnumed.112.105379 pmid:23864718

    Abstract/FREE Full Text
17. 17.↵
    1. Nam Y,
    2. Gho SM,
    3. Kim DH, et al

    . Imaging of nigrosome 1 in substantia nigra at 3T using multiecho susceptibility map-weighted imaging (SMWI). J Magn Reson Imaging 2017;46:528–36 doi:10.1002/jmri.25553 pmid:27859983

    CrossRefPubMed
18. 18.↵
    1. Gho SM,
    2. Liu C,
    3. Li W, et al

    . Susceptibility map-weighted imaging (SMWI) for neuroimaging. Magn Reson Med 2014;72:337–46 doi:10.1002/mrm.24920 pmid:24006248

    CrossRefPubMed
19. 19.↵
    1. Hughes AJ,
    2. Daniel SE,
    3. Kilford L, et al

    . Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–84 doi:10.1136/jnnp.55.3.181 pmid:1564476

    Abstract/FREE Full Text
20. 20.↵
    1. Shulman KI,
    2. Herrmann N,
    3. Brodaty H, et al

    . IPA survey of brief cognitive screening instruments. Int Psychogeriatr 2006;18:281–94 doi:10.1017/S1041610205002693 pmid:16466586

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Nasreddine ZS,
    2. Phillips NA,
    3. Bedirian V, et al

    . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–99 doi:10.1111/j.1532-5415.2005.53221.x pmid:15817019

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Goetz CG,
    2. Tilley BC,
    3. Shaftman SR

    , Movement Disorder Society UPDRS Revision Task Force, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129–70 doi:10.1002/mds.22340 pmid:19025984

    CrossRefPubMedWeb of Science
23. 23.↵
    1. Hoehn MM,
    2. Yahr MD

    . Parkinsonism: onset, progression, and mortality. 1967. Neurology 2001;57:S11–S26 pmid:11775596

    PubMedWeb of Science
24. 24.↵
    American Academy of Sleep M. International Classification of Sleep Disorders. Diagnostic and Coding Manual 2005 51–55
25. 25.↵
    1. Pirker W,
    2. Katzenschlager R

    . Gait disorders in adults and the elderly: a clinical guide. Wien Klin Wochenschr 2017;129:81–95 doi:10.1007/s00508-016-1096-4 pmid:27770207

    CrossRefPubMed
26. 26.↵
    1. Elble RJ

    . Diagnostic criteria for essential tremor and differential diagnosis. Neurology 2000;54:S2–S6 pmid:10854344

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Shin HW,
    2. Chung SJ

    . Drug-induced parkinsonism. J Clin Neurol 2012;8:15–21 doi:10.3988/jcn.2012.8.1.15 pmid:22523509

    CrossRefPubMed
28. 28.↵
    1. Bae YJ,
    2. Kim JM,
    3. Kim KJ, et al

    . Loss of substantia nigra hyperintensity at 3.0-T MR imaging in idiopathic REM sleep behavior disorder: comparison with (123)I-FP-CIT SPECT. Radiology 2018;287:285–93 doi:10.1148/radiol.2017162486 pmid:29232183

    CrossRefPubMed
29. 29.↵
    1. Senn S

    . Review of Fleiss, statistical methods for rates and proportions. Res Synth Methods 2011;2:221–22 doi:10.1002/jrsm.50 pmid:26061787

    CrossRefPubMed
30. 30.↵
    1. Sommer U,
    2. Hummel T,
    3. Cormann K, et al

    . Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004;19:1196–202 doi:10.1002/mds.20141 pmid:15390014

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Jennings D,
    2. Siderowf A,
    3. Stern M

    , PARS Investigators, et al. Imaging prodromal Parkinson disease: the Parkinson associated risk syndrome study. Neurology 2014;83:1739–46 doi:10.1212/WNL.0000000000000960 pmid:25298306

    Abstract/FREE Full Text
32. 32.↵
    1. Moccia M,
    2. Pappata S,
    3. Picillo M, et al

    . Dopamine transporter availability in motor subtypes of de novo drug-naive Parkinson’s disease. J Neurol 2014;261:2112–8 doi:10.1007/s00415-014-7459-8 pmid:25119838

    CrossRefPubMed
33. 33.↵
    1. Postuma RB,
    2. Gagnon JF,
    3. Bertrand JA, et al

    . Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015;84:1104–13 doi:10.1212/WNL.0000000000001364 pmid:25681454

    Abstract/FREE Full Text
34. 34.↵
    1. Haas BR,
    2. Stewart TH,
    3. Zhang J

    . Premotor biomarkers for Parkinson’s disease—a promising direction of research. Transl Neurodegener 2012;1:11 doi:10.1186/2047-9158-1-11 pmid:23211054

    CrossRefPubMed
35. 35.↵
    1. Fearnley JM,
    2. Lees AJ

    . Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114:2283–301 doi:10.1093/brain/114.5.2283 pmid:15390014

    CrossRefPubMedWeb of Science
36. 36.↵
    1. Oh M,
    2. Kim JS,
    3. Kim JY, et al

    . Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. J Nucl Med 2012;53:399–406 doi:10.2967/jnumed.111.095224 pmid:22323779

    Abstract/FREE Full Text
37. 37.↵
    1. Berg D,
    2. Hochstrasser H

    . Iron metabolism in Parkinsonian syndromes. Mov Disord 2006;21:1299–310 doi:10.1002/mds.21020 pmid:16817199

    CrossRefPubMedWeb of Science
38. 38.↵
    1. Marek K,
    2. Seibyl J,
    3. Eberly S, et al

    . Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 2014;82:1791–97 doi:10.1212/WNL.0000000000000424 pmid:24759846

    Abstract/FREE Full Text
39. 39.↵
    1. Rhodes SL,
    2. Ritz B

    . Genetics of iron regulation and the possible role of iron in Parkinson’s disease. Neurobiol Dis 2008;32:183–95 doi:10.1016/j.nbd.2008.07.001 pmid:18675357

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Zecca L,
    2. Stroppolo A,
    3. Gatti A, et al

    . The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci U S A 2004;101:9843–48 doi:10.1073/pnas.0403495101 pmid:15210960

    Abstract/FREE Full Text
41. 41.↵
    1. Cheng Z,
    2. Zhang J,
    3. He N, et al

    . Radiomics features of the nigrosome-1 region of the substantia nigra: Using quantitative susceptibility mapping to assist the diagnosis of idiopathic Parkinson’s disease. Front Aging Neurosci 2019;11:167 doi:10.3389/fnagi.2019.00167 pmid:31379555

    CrossRefPubMed
42. 42.↵
    1. Lee J,
    2. Lee AL,
    3. Park J-H, et al

    . The clinical application of nigrosome 1 detection on high-resolution susceptibility-weighted imaging in the evaluation of suspected Parkinsonism: the real-world performance and pitfalls. PLoS One 2020;15:e0231010 doi:10.1371/journal.pone.0231010 pmid:32240236

    CrossRefPubMed
43. 43.↵
    1. Hubbuch M,
    2. Farmakis G,
    3. Schaefer A, et al

    . FP-CIT SPECT does not predict the progression of motor symptoms in Parkinson’s disease. Eur Neurol 2011;65:187–92 doi:10.1159/000324732 pmid:21412004

    CrossRefPubMed